Meryl Squires

Founder, President and CEO of Merix Pharmaceutical Corp. a company devoted to creating very effective, safer, more natural medicinal products for the retail and pharmaceutical marketplaces. With undergraduate studies in Biology and Psychology, Ms. Squires received awards for leadership and academics. Since 1978, Ms Squires' course of study has been specializing in bio-medical research, phyto-pharmacognosy and application of phyto-pharmaceuticals.

Ms. Squires also researches consumer products. In 1989 Ms. Squires is credited with inventing Viracea® a novel bio-technology demonstrating useful application against the herpes virus that causes cold sores and presently licensed into retail and professional products including RELEEV® brand products, Proginicin® dental products, and Regal Horse Products. She now owns worldwide patents on this formula and has grown the consumer products division of Merix to a projected $10 Million in only 3 years due to the success of RELEEV 1- Day Cold Sore Symptom Treatment.

After years of development by Ms. Squires, Merix has entered the dental market with their recent launch of Proginicin, a treatment for gum disease and dental procedures. Collaborative research and development liaisons are planned with outside firms to assist in the development of Viracea into pharmaceutical products.

In 2005 Ms. Squires was chosen as an Ernst & Young Entrepreneur of the year finalist. Highly visible, Ms. Squires has been a professional speaker seen on talk shows and speaking to large audiences. Honors include: Phi Theta Kappa; Dean's List; Dean's Honors; Leadership Award, Psychology Society Harper College; Leadership Award, Biological Society Harper College; Merit Scholarship. Publications: American Virology Society: Antiviral Activity of Viracea in Herpes (HSV1 & HSV2); Antiviral
Activity of Viracea in Acyclovir Resistant Strains of Herpes
(HSV1 & HSV2); BROADBASED ANTI-INFECTIVE ACTIVITY
OF VIRACEA.